MeiraGTx Holdings PLC

NASDAQ:MGTXUnited States

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.

Contact Information

Headquarters

450 EAST 29TH STREET, 14TH FLOORNEW YORK, NY, United States 10016

Phone

646-860-7985

Fax

---

Executives

Independent Chairman of the Board

Keith Harris

President, Chief Executive Officer, Director

Alexandria Forbes

Chief Financial Officer, Chief Operating Officer

Richard Giroux

General Counsel, Secretary

Robert Wollin

Chief Development Officer

Stuart Naylor